Complain about a product or service

Study: New Blood Pressure Rx Has Fewer Side Effects

Study also finds orlistat helps relieve hypertension

April 1, 2008

• Statins Could Prevent More Heart Attacks • High Blood Pressure Control More Elusive for Black Americans • Low Potassium May Equal High Sodium as Blood Pressure Risk • Grapes Might Help Manage Blood Pressure • Statins May Help Prevent Miscarriages • FDA Recommends No Change In Use Of Statins • Statins May Help Reduce Blood Pressure • New Guidelines for Stubborn High Blood Pressure • Study: New Blood Pressure Rx Has Fewer Side Effects • Weight Loss Found Effective in Reducing Blood Pressure • Blood Pressure Patients Ignore Recommended Diet • Study: Beetroot Juice Can Beat High Blood Pressure • How Much Sodium Is Too Much? It Depends • Blood Pressure: What You Don't Know Can Kill You • Diuretics May Be Best Blood Pressure Treatment • Researchers Find Gene Implicated in High Blood Pressure • FDA Approves New Beta Blocker • VA Study Finds Seasonal Differences in Blood Pressure • Heavy Drinking Linked To High Blood Pressure In Older Men • Yoga May Help Control Blood Pressure • High Blood Pressure Often Undiagnosed in Children, Teens • Small Amounts Of Exercise Can Lower Blood Pressure • Cocoa, Not Tea, Appears To Lower Blood Pressure • FDA Green Lights New Blood Pressure Drug • Researchers Find Chinese Herb Reduces Blood Pressure • Moderate Drinking May Be OK for Men with High Blood Pressure • High Blood Pressure Not Well Controlled Among Older Patients • Small Doses Of Exercise Can Lower Blood Pressure • Medical Experts Call for FDA Action on Salt --- • Health News

A major Canadian-led global study has found that a new blood pressure drug, telmisartan, is as effective as the popular drug ramipril in reducing cardiovascular death in high risk patients and it has fewer side effects.

Results of the study, led by Dr. Salim Yusuf, director of the Population Health Research Institute at McMaster University and Hamilton Health Sciences, were published on-line by the New England Journal of Medicine.

Previous studies such as the Heart Outcomes Prevention Evaluation Trial (HOPE) demonstrated that angiotensin converting enzyme (ACE) inhibitors such as ramipril reduce cardiovascular death, myocardial infarction, strokes and heart failure in high risk individuals. However, a significant proportion (about 20 percent) of patients are unable to tolerate an ACE-inhibitor due side effects such as coughing, hypotension or swelling.

An alternate therapy, telmisartan, which is an angiotensin II receptor blocker, proved to be at least as effective and better tolerated, offering clinicians and patients an important alternative.

“This study is of clinical importance because it demonstrates that telmisartan is an effective and safe alternative to ramipril. This means both patients and physicians have choices and can use telmisartan where appropriate with a high degree of confidence,” said Yusuf.

Investigators from 733 centers in 40 countries collaborated in conducting the study, which enrolled 25,620 patients with coronary heart disease or diabetes plus additional risk factors and were over the age of 55 years of age, but did not have evidence of heart failure.

Patients were randomized to receive ramipril 10-mg a day, telmisartan 18-mg a day or the combination of the two. The mean duration of follow-up of the study was 55 months.

Telmisartan and ramipril were found to be equally effective but telmisartan was better tolerated than ramipril with the chief differences being lower rates of coughing and lower rates of angioneurotic edema (a life-threatening swelling of the throat and airways). There was a small excess of minor symptoms related to hypotension such as dizziness with telmisartan.

“All people who have cardiovascular disease or diabetes with organ target damage and physicians managing these diseases should be interested in the results of this important trial,” said Dr. Gilles Dagenais, cardiologist at the Laval University Heart and Lung Institute, Quebec City.

“If it’s possible to have access to a medication that can prevent serious cardiovascular events but with fewer side effects and better compliance than what’s currently available, it will also have a great impact on their quality of life.”

The trial is very important because “it addresses the question of how we can best prevent heart attack, stroke, heart failure, cardiovascular death and other outcomes such as diabetes,” said Dr. Koon Teo, professor of medicine at McMaster University and head of clinical trials in the Population Health Research Institute at Hamilton Health Sciences.

“These conditions affect millions of people around the world and if we can find a better treatment that improves these outcomes we’re doing a lot of good.”

Surprisingly, combination therapy did not offer any additional benefit but was associated with a higher rate of hypotension related side effects including fainting. There was also an increase in discontinuations for hyperkalemia (high potassium levels).

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.